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Abstract: Glanzmann’s thrombasthenia (GT) is a genetic platelet surface receptor disorder 
of GPIIb/IIIa (ITG αIIbβ3), either qualitative or quantitative, which results in faulty platelet 
aggregation and diminished clot retraction. Spontaneous mucocutaneous bleeding is common 
and can lead to fatal bleeding episodes. Control and prevention of bleeding among patients with 
GT is imperative, and remains challenging. Local measures, including anti-fibrinolytic therapy, 
with or without platelet transfusions, used to be the mainstay of therapy. However, in recent 
years the use of recombinant factor VIIa (rFVIIa) has increased significantly, with excellent 
response rates in treating and preventing hemorrhage among GT patients. Gene therapy and 
stem cell transplantation offer a potential cure of this disease, but both are costly and remain 
experimental at this point. This manuscript offers a comprehensive review of our understanding 
of GT and the available treatment options.
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Introduction
Platelets are a central component of many restorative physiological processes, including 
hemostasis. During hemostasis, damaged subendothelium releases adhesive proteins 
(ie, collagen and thromboplastin) and fibrinogen, which bind with aggregated plate-
lets at the site of injury, forming a platelet plug. Platelets then provide a surface and 
phospholipid source for attachment of coagulation cofactors. Subsequent activation 
of the coagulation pathways prompts fibrin attachment to activated platelets, creating 
a thrombus. Any disruption in platelet function, whether acquired or inherited, will 
generate bleeding.
Acquired platelet disorders are more likely to be encountered in clinical practice 
than their inherited counterpart, and often result from the initiation of medications or 
underlying medical conditions. In contrast, inherited platelet disorders are rare, and until 
recently, have been under less scrutiny. One of the most recognized and clearly defined 
disorders of inherited abnormal hemostasis today is Glanzmann’s thrombasthenia (GT), 
a disease that has helped pave the way for key research findings in hematology.
Eduard Glanzmann was a Swiss pediatrician who first discovered the condition of 
thrombasthenia in 1918.4 Formerly known as “hereditary hemorrhagic thrombasthenia”, 
Glanzmann recognized a disorder that was not attributed to an abnormal number of 
platelets, but rather a faulty clot retraction, which paved the way for future work.4 
According to a biographical account, Glanzmann’s encounter with a symptomatic 
7-year-old girl led him to study the disease within families. Noting a familial pattern 
and symptoms manifesting in children, he considered a possible hereditary component. 
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The disease was later defined as a heritable platelet disorder 
secondary to a dysfunction in GPIIb/IIIa complex.
Today GT receives much recognition, as it was one of 
the first disorders to define GPIIb/IIIa as a platelet receptor 
for adhesive molecules (such as VWF and fibrinogen). The 
disease also served as a template for understanding processes 
of platelet aggregation as well as targets for therapeutic 
measures.
Pathogenesis of GT
GT is an autosomal recessive platelet surface receptor 
disorder of GPIIb/IIIa (ITG αIIbβ3), either qualitative or 
quantitative, which results in faulty platelet aggregation and 
diminished clot retraction.
The GPIIb/IIIa, or ITG αIIbβ3, is a large heterodimeric 
cell transmembrane receptor comprised of a larger αIIb and 
a smaller β3 subunit. These subunits are non-covalently 
linked, allowing for duplex signaling between the cell mem-
brane and extracellular matrix, while instituting intracellular 
signaling pathways. Electron microscope images of the het-
erodimer have shown an 8×12 nm nodular head and two 18 
nm stalks.12 The stalks extend through the cell, and contain 
the cytoplasmic and transmembrane domains that serve as 
attachment points for intracellular signaling molecules and 
proteins, while the bent head contains the ligand-binding 
site.12 The β3 subunit consists of large, disulfide epidermal 
growth factor (EGF)-domains responsible for activation of 
ITG αIIbβ3 as a whole. The calcium binding sites involved in 
complex formation and platelet-platelet adherence are located 
on the β-propeller region of the αIIb subunit.6 The receptor 
head functionality – binding fibrinogen, VWF, vitronectin 
and fibronectin – is necessary for platelet aggregation. ITG 
αIIbβ3 controls cell-to-cell communications by regulation 
of cell migration, platelet aggregation and adhesion, and the 
formation of a thrombus.
Roughly 100,000 copies of the GPIIb/IIIa receptor are 
expressed along a platelet’s surface, which differs by two-
fold between individuals.6,23 The gene ITGA2B, located 
on chromosome 17q21.31, codes for the platelet GPαIIb, 
while the gene ITGB3 encoding for the glycoprotein subunit 
IIIa lies on chromosome 17q21.32. Mutations have been 
found more commonly in the ITGA2B gene, possibly due 
to the voluminous number of exons when compared to the 
ITGB3 gene (30 compared to 15).6,10 Deletions, insertions, 
frameshifts, nonsense, and missense mutations have been 
frequently recognized. Missense mutations have been further 
studied, and display interruption in integrin maturation or 
subunit formation. Biogenesis of ITG αIIbβ3 arises from the 
hematopoietic stem cell. The subunit αIIb is arranged from 
a single peptide, and is closely linked to the megakaryocyte 
lineage, whereas β3 is linked to the vitronectin receptor 
(αvβ3) involved in transport processes, with distribution 
among multitudes of tissues.10 Both subunits are amassed 
from endoplasmic reticulum precursors, with further process-
ing occurring in the Golgi apparatus. The αvβ3 receptor will 
be most abundant on platelets in patients with an ITGA2B 
mutation. Both αIIbβ3 and αvβ3 will be absent when a 
mutation prevents β3 synthesis, but a missense mutation 
in β3 can have varying effects. For example, mutations in 
β3 Leu262Pro and Ser162Leu have been shown to provide 
residual αIIbβ3 platelet complexes with the capacity to bind 
fibrin and retract clots, but, when stimulated, are incapable of 
adhering fibrinogen. In contrast, a mutation in β3 Leu196Pro 
is able to sustain partial clot retraction.2,6 A review by Nur-
den et al more closely examined the β-propeller ectodomain 
mutations of the αIIb subunit. Nurden et al concluded that 
a large series of mutations affecting the β-propeller domain 
interrupted calcium binding and had numerous deleterious 
effects on αIIbβ3 expression and function, giving rise to the 
different types of GT.5 Mutations in the αIIb subunit that 
allow for partial complex formation were found to be distant 
from the junction between αIIb and β3, inferring a variant 
form of GT. Different effects are noted between mutations 
occurring in either subunit of αIIbβ3, and between αIIbβ3 
and αvβ3; however, αvβ3 is more resilient to change than 
αIIbβ3. Some mutations of αIIbβ3 do not lead to GT. For 
example, Kashiwagi et al recently described three gain 
of function mutations, ITGA2B p.Gly991Cys, ITGA2B 
p.Phe993del, and ITGB3 p.(Asp621_Glu660del), that led to 
a highly activated conformation of αIIbβ3 and spontaneous 
tyrosine phosphorylation of FAK in transfected cells. These 
mutations resulted in abnormalities in both platelet morphol-
ogy and number, with impaired surface αIIbβ3 expression, 
but did not lead to GT.9
Homozygous or heterozygous mutations found at 
either gene locus determine the severity of abnormality 
seen in GT. Mutations can arrest subunit manufacturing, 
impede complex formation, and/or inhibit intracellular 
trafficking. When complex formation is hindered, residual 
subunits of αIIb or β3 degrade. Based on the expression 
and functionality of residual subunits, GT is classified into 
three types: ,5% of residual αIIbβ3 signifies type I GT; 
5%–20% of residual αIIbβ3 comprises type II GT; and 
rarely, .20% of residual αIIb β3, with dysfunctional prop-
erties, constitutes variant-type GT. Early work by George 
et al failed to correlate the subtype of GT with severity 
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of bleeding.10 However, it has been noted by Fiore et al 
that phenotypic bleeding is more influenced by a mutation 
in the ITGB3 gene.6
Acquired GT is commonly the result of an autoantibody 
attack on platelet αIIbβ3, or isoantibodies inhibiting proper 
function. The production of autoantibodies has been associated 
with platelet transfusions, as well as numerous hematologic 
conditions, including immune thrombocytopenic purpura, non-
Hodgkin’s lymphoma, multiple myeloma, myelodysplastic syn-
drome, hairy cell leukemia, and acute lymphoblastic leukemia. 
In a case report done by Blickstein et al, a patient with systemic 
lupus erythematosus presented in adulthood with degrees of 
mucocutaneous bleeding secondary to antibody production 
against GPIIb/IIIa.5 Also, some anti-thrombotic therapies use 
αIIbβ3 antagonists, such as abciximab, eptifibatide, and tiro-
fiban, for treatment of acute coronary events, which can trigger 
a transient GT-like state.10
Incidence and prevalence
It is estimated that one in 1,000,000 individuals have GT, 
though the exact number is unknown.14 Studies have shown 
a slight predominance in women compared to men (58% 
versus 42%), consistent with its mode of inheritance.7 GT 
can be found in individuals across the globe, but is more 
common in ethnic groups that display higher incidences of 
consanguinity, such as Iraqi Jews, selective Arab populations 
(eg, Palestinian), and French Gypsies. According to one study, 
the disease has a high prevalence among the French Gypsy 
Manouche community, with approximately 150 cases of 300 
in France from that origin. The inflated number among these 
population groups illustrates a founder effect.2
Clinical presentation
GT may manifest itself shortly after birth, beginning with 
purpura in the neonate, and followed by episodes of mucocu-
taneous bleeding and spontaneous bruising. The majority of 
patients will be diagnosed before the age of 5, with recurring 
episodes of epistaxis and gingival bleeding being among the 
most common manifestations. In one Parisian study, 84% 
of patients with GT required red blood cell transfusion. 
The most common cause of epistaxis in any child is digital 
manipulation; however, in patients with GT, severe bleed-
ing can occur in this highly vascularized area, which can be 
fatal. While fatal bleeding episodes can occur at any point 
in the lifespan of a patient with GT, the prevalence of severe 
bleeding does decrease with age.7
To date, there is little evidence to support any correla-
tion between gene defect in GT and the severity of bleeding, 
as affected individuals demonstrate different bleeding tenden-
cies, even within the same family or ethnic group.10 In some 
cases, disproportionately severe bleeding after minor trauma 
or surgery may be the introductory sign of the condition. 
Excessive bleeding during circumcision has been noted, and is 
often the reason for investigation and diagnosis of GT in males. 
In some cases, women have not been diagnosed until menar-
che, when severe blood loss due to menorrhagia has required 
transfusion, as reported in a study by George et al. Labor and 
delivery is of special concern, as women are at increased risk 
for severe or fatal hemorrhage during this time.7
Diagnosis
The diagnosis of GT is often overlooked, as the condition 
shares common clinical and laboratory features with other 
acquired platelet disorders. One must remember to include 
GT in the differential diagnosis, carefully analyzing the 
medical history (eg, asking about unprovoked bruising 
or bleeding episodes, or episodes of severe bleeding after 
minor trauma), family history (eg, inquiring about possible 
consanguinity), and clinical presentation (eg, examining for 
purpura and ecchymoses).
When considering a diagnosis of GT, selecting the 
appropriate laboratory evaluation is essential. For example, 
a normal platelet count on a routine blood smear does not 
rule out a diagnosis of GT, as patients with GT usually show 
no abnormalities in the platelet count. The complete blood 
count may be entirely normal, or may reveal iron deficiency. 
The prothrombin time and activated partial thromboplastin 
time will also be normal. However, the bleeding time will be 
prolonged, which warrants further investigation.
Light transmission aggregometry (LTA) is widely 
accepted as the gold standard diagnostic tool for assessing 
platelet function. Centrifuged platelet-rich plasma samples 
are monitored before and after the addition of an agonist 
(ADP, collagen, epinephrine, arachidonic acid, ristocetin, 
thrombin receptor activating peptide, and thromboxane A2 
mimetic), assessing shape change, lag phase, percent of 
aggregation, slope of aggregation, and deaggregation. This 
test is highly specific for GT, as platelet aggregation fails to 
occur with any agonist, except ristocetin, where the reaction 
is preserved. Although this test yields specific data, LTA is 
very time consuming and personnel dependent, requiring the 
use of experienced laboratories. It is also more difficult to 
obtain platelet-rich plasma in patients with thrombocytopenia 
and in pediatric patients under the testing guidelines.
Platelet function analyzer (PFA) is a highly sensitive 
test for detecting GT. The PFA assay uses collagen + 
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ADP- and collagen + epinephrine-embedded cartridges to 
mimic a damaged vessel endothelium. As citrated whole 
blood flows at a high shear stress rate through these car-
tridges, platelets bind, creating a platelet plug. The PFA 
assay is prolonged among patients with GT.6
Flow cytometry can be beneficial, as GT includes glyco-
protein receptor deficiency and/or dysfunction. Flow cytom-
etry will measure distinct platelet receptor densities using a 
variety of monoclonal antibodies to those receptors, singling 
out the deficient αIIbβ3. Under flow cytometric analysis, 
CD41 and CD61 levels are markedly decreased or absent, 
while normal levels of CD42, and identification of deficient 
and non-functional αIIbβ3 can be expressed, consistent with 
a diagnosis of G.10
The best way to diagnose GT in its entirety is through 
mutation analysis. Genomic DNA sequencing of the 45 exons 
comprising the αIIbβ3 unit, along with the splice sites of the 
ITGB3 and ITGA2B gene, should be investigated, and the 
established mutations should be confirmed with a second 
DNA sample analysis.
Overall, the diagnosis of GT includes the presence of 
normal platelet count (typically on the lower end of normal), 
prolonged bleeding time, and prolonged PFA time. Platelets 
fail to aggregate under the conditions utilized in LTA, which 
is uniquely indicative of GT.
Treatment
All patients with GT require management by a specialist, 
and should be registered with a 24-hour center capable of 
handling diagnosis and treatment.5,6 Patients with GT do not 
need therapy on a regular basis, but will always require treat-
ment during surgical procedures, controlling bleeding after 
injury, and during spontaneous bleeding episodes.
Patient education
As patients will likely receive transfusions of blood products 
at least once in their lifetime, all patients should receive immu-
nization against hepatitis B. Patients should also be advised 
to avoid contact sports as well as the use of aspirin and non-
steroidal anti-inflammatory drugs.6 In order to mitigate the 
risk of gingival bleeding, patients should maintain excellent 
oral hygiene and participate in regular dental visits. Women 
in particular, due to the consequences of menorrhagia, need 
monitoring for iron deficiency, and should be placed on iron 
supplementation if necessary. Patients should be HLA typed 
at diagnosis, and monitored for HLA and anti-platelet antibod-
ies regularly.6 Patients should also be counseled that bleeding 
from a minor wound, the gingiva, or the nose may be able to 
be stopped by applying pressure, and/or by taking an oral anti-
fibrinolytic, but to seek medical attention if bleeding persists.
General treatment concepts
The current standard of treatment of bleeding episodes in 
patients with GT is the use of local measures alone or in 
conjunction with anti-fibrinolytic therapy first, followed by 
platelet transfusion, and rFVIIa if bleeding persists.7 Local 
measures include the use of compression, fibrin sealants, 
and topical thrombin.3 When possible, platelet concentrates 
should be single-donor derived and HLA-matched due to 
the risk of developing alloantibodies against the platelet 
glycoproteins, αIIbβ3, or αIIbβ3, and/or the HLA antigens 
with repeated transfusions. If HLA-matched platelets are 
not available, patients should receive leukocyte-reduced 
platelets, as this has been shown to reduce the rate of HLA 
immunization. Patients with severe bleeding episodes should 
continue to receive platelet transfusions for 48 hours after the 
cessation of bleeding, and until wound healing has occurred 
in patients undergoing surgery. The PFA assay time will 
normalize with adequate transfusions.2
Management of minor  
to moderate bleeding
For mild to moderate bleeding episodes, local measures, and/
or anti-fibrinolytic drugs may resolve bleeding (Figure 1). 
Anti-fibrinolytic drugs work particularly well for muco-
cutaneous bleeding, and have been shown to successfully 
decrease bleeding during dental procedures, in combination 
with local measures. Local measures include compression, 
gelatin sponges, fibrin sealants, and topical thrombin.6 
Anti-fibrinolytic agents include tranexamic acid and epsilon 
aminocaproic acid. These agents, used alone or as adjunc-
tive therapy with rFVIIa, have proven to be useful and safe 
agents in minimizing or resolving bleeding in patients with 
GT in multiple settings. As both agents can be given orally 
or intravenously, they have been used successfully for the 
treatment of epistaxis, gingival bleeding, and menorrhagia, 
and also as prophylaxis prior to dental extractions and other 
minor surgical procedures. The use of anti-fibrinolytics in 
cases of hematuria should be avoided due to the risk of clots 
in the urinary tract, and should be used with caution in patients 
undergoing procedures carrying a high risk of thrombosis.6
Management of epistaxis
Epistaxis is one of the most common bleeding manifestations in 
patients with GT.1,2,5 Patients may respond to compression, topi-
cal thrombin, anti-fibrinolytics, nasal packing, or a combination 
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New onset bleeding or urgent procedure
Check for history of antibodies and
platelet refractoriness. Pre-op PFA-100
No anitbodies and
no refractoriness
Random donor
platelets,
consider rFVIIa
Antibodies and
refractory
HLA matched
platelet,
consider rFVIIa 
Reassess bleeding response
No bleeding
Platlets and rFVIIa
as needed 
Persistant
bleeding, normal 
PFA-100 
Assess for
surgical site,
local measures  
Persistant
bleeding,
prolonged PFA-
100  
Check platelet
antibody, r/o DIC
Antibodies but
not refractory
HLA matched
platelet,
consider rFVIIa
Figure 1 Management algorithm for major bleeding episode or urgent invasive 
procedure.
Abbreviations: PFA, platelet function analyzer; DiC, disseminated intravascular 
coagulopathy; r/o, rule out.
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of these, but these methods are not always effective.12 A ret-
rospective study comparing different methods used to control 
local nasal hemorrhage in children with GT found that the 
use of anterior and posterior packing only, without adjunctive 
prothrombotic agents, was at least as effective as the same 
procedure with the use of a prothrombotic agent. If conven-
tional methods fail to control bleeding, further treatment with 
platelet transfusion and/or rFVIIa is necessary.12 Interestingly, 
nasal packing with salt pork strips has been used to successfully 
control life threatening nasal hemorrhage in a hemodynamically 
unstable child with GT, after anti-fibrinolytic agents, rFVIIa, 
nasal cautery, and nasal packing with synthetic materials had 
failed to control the bleeding.11
Management of menorrhagia
Anti-fibrinolytic agents are first-line therapy to control 
menorrhagia. If these agents fail, hormone supplementation 
with either progesterone alone or progesterone with estro-
gen should be used. A continuous regimen of an estrogen-
progestin oral contraceptive agent or intramuscular depot 
medroxyprogesterone acetate given once every 3 months 
has been used successfully in women with GT. Hormonal 
intrauterine devices have also been used to reduce bleeding, 
with or without the use of an anti-fibrinolytic agent.3
Severe menorrhagia, which plagues many women with GT 
and can be seen with menarche, can be treated with high-dose 
conjugated estrogen intravenously for 24–48 hours, followed 
by high doses of an oral combination of estrogen–progestin. 
However, intensive menstrual bleeding does not always 
respond to typical therapy. rFVIIa has been utilized with 
anecdotal success in GT when anti-fibrinolytics and platelet 
transfusions did not control excessive menorrhagia.4 Surgical 
therapy such as hysterectomy or endometrial ablation are also 
therapeutic options for severe menorrhagia, but should be 
reserved for women who no longer desire pregnancy.
Management of postpartum  
hemorrhage
Pregnancy in patients with GT is associated with increased 
risk of primary and secondary postpartum hemorrhage, as well 
as increased risk of fetal bleeding.5 Guidelines have advocated 
for the use of either platelet transfusions, or rFVIIa in com-
bination with an anti-fibrinolytic, as prophylaxis for vaginal 
delivery. A systematic review of management and outcomes 
of 35 pregnant women with GT revealed that hemorrhage 
during or after delivery is common and severe, and occurred 
up to 20 days postpartum. Patients who were not given any 
platelet transfusions as prophylaxis were more likely to experi-
ence postpartum hemorrhage than patients who were given 
platelet transfusion as prophylaxis (63% versus 38%). The use 
of rFVIIa as prophylaxis was documented in three pregnan-
cies, either alone or in combination with platelets, and did 
not prevent hemorrhage in those cases.5 However, successful 
use of rFVIIa for persistent postpartum hemorrhage has been 
reported elsewhere in the literature.6 Maternal platelet alloan-
tibodies were documented in 16 pregnancies, and plasma 
exchange successfully reduced the alloantibody titer in one 
case. Four of the 16 cases resulted in neonatal deaths, three of 
which resulted from intracranial hemorrhage between 24 and 
31 weeks gestation. All women with GT should be monitored 
for platelet alloantibodies throughout pregnancy.5
Management with desmopressin
Desmopressin (DDAVP) causes the release of VWF, FVIII, 
and tissue plasminogen activator into the plasma. DDAVP has 
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Elective procedure
1. HLA antibodies and refractory
or
2. GPIIb/IIIa antibodies
HLA-matched platelets +/−rFVIIa
Known HLA antibodies
HLA-matched platelets +/−rFVIIa
PFA-100 prolonged: consider antibody removal. Further HLA matched platelets 
+/−rFVIIa
No antibodies and not refractory
HLA-matched platelets +/−rFVIIa
1. Test for alloantibodies and
    platelet refractoriness
2. Preoperative PFA-100
Figure 2 Management algorithm for elective surgical procedures in Glanzmann’s thrombasthenia.
Abbreviations: PFA, platelet function analyzer; HLA, human leukocyte antigen.
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no direct effect on platelets, and samples from patients treated 
with DDAVP do not show a significant effect on platelet 
deposition on collagen ex vivo.1 While DDAVP is successful 
in treating other platelet disorders, there is currently little 
data to support its use in patients with GT.6 In one small case 
series, DDAVP as a single agent successfully treated one out 
of nine patients with GT.1
Role of transfusions in the  
management of GT
Platelet transfusion allows the partial correction of the 
functional defect in patients with GT and is considered 
standard therapy for patients when local measures and/or 
anti-fibrinolytics fail to control bleeding.4 It is also the stan-
dard prophylaxis in GT patients undergoing major surgery 
(Figure 2).3 It is not uncommon for patients with severe bleed-
ing after trauma or delivery to require multiple platelet and/or 
RBC transfusions. Repeated platelet transfusions are associ-
ated with the formation of isoantibodies to GPIIb/IIIa isotopes 
and/or HLA isotopes, and it has been estimated that between 
30% and 70% of patients will develop alloantibodies after 
platelet transfusion.2,3 A study by Santoro et al followed 17 GT 
patients over 30 years, 16 of whom were transfused at least 
once with platelets and/or RBCs. Alloantibodies developed 
in 25% of the patients transfused; two patients were positive 
for anti-HLA antibodies, one patient was positive for anti-ITG 
αIIbβ3, and one developed both types of alloantibodies.5 In 
the international survey conducted by Poon et al, a similar 
prevalence of anti-HLA alloantibodies was reported, and 17 
out of the 23 patients who were platelet refractory in the survey 
had anti-platelet alloantibodies.7 Platelet alloimmunization 
can lead to relative or absolute platelet refractoriness, resulting 
in accelerated destruction of platelets and therapeutic failure 
of platelet transfusions. Therefore, HLA-matched platelets 
are recommended to avoid possible alloimmunization.5 
Before the widespread use of rFVIIa, absolute refractoriness 
due to platelet alloantibodies was traditionally managed by 
plasmapheresis or IVIG, followed by platelet transfusion.2 
rFVIIa is now recommended for use in patients who do not 
respond to platelet transfusions, with or without the presence 
of platelet alloantibodies.6
Platelet alloantibodies have been successfully removed 
prior to surgery by immunoadsorption on protein A 
Sepharose.4,5 In a series of three type I GT patients with 
alloantibodies, immunoadsorption on protein A Sepharose 
successfully cleared anti-GPIIb/IIIa antibodies on five 
different occasions, including episodes with life threatening 
hemorrhaging. However, the effect is transient; the response 
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to platelet transfusion lasted 5 to 13 days in the series. The 
widespread use of the procedure is limited by the requirement 
of large vascular access and the need for the procedure to be 
performed in dedicated centers.4
rFviia
rFVIIa was first used successfully for severe, uncontrolled 
hemorrhaging in a 2-year-old boy with GT in 1996.1,2 Since 
then, its use has continued throughout the world, and while 
it successfully manages bleeding in most patients with GT, 
it is not effective in all patients.
NovoSeven RT is a recombinant activated human FVII 
commercial product that is available in North America, 
Europe, Australia, and Japan. It was first approved for use 
in the US as a hemostatic agent in patients with acquired 
hemophilia A and B, antibodies to factors VIII or IX, and 
those with congenital deficiency of FVII. In 2014, the US 
Food and Drug Administration (FDA) additionally approved 
NovoSeven RT for the treatment of bleeding episodes and 
perioperative management of patients with GT who are 
refractory to platelet transfusions, with or without the pres-
ence of anti-platelet alloantibodies.4
Mechanism of action of rFviia
The mechanism by which rFVIIa controls bleeding in some 
GT patients but not others has not been fully delineated. 
Through a tissue factor-independent mechanism, it is thought 
to weakly bind to the surface of platelets and increase 
activation of factor IX and X, thereby increasing thrombin 
generation. Doses of 90 mcg/kg and above have been shown 
to significantly increase thrombin generation. The increased 
amount of thrombin enhances platelet adhesion and promotes 
platelet aggregation, including those lacking GPIIb/IIIa.3 
This has been demonstrated in perfusion models, in which 
rFVIIa increased thrombin generation and fibrin deposition, 
and partially restored platelet aggregation.7
Use of rFviia in GT
While not 100% efficacious, the high rates of success and 
relatively low risks associated with using rFVIIa as treat-
ment or prevention of bleeding in patients with GT has been 
well documented, especially in those who are refractory to 
platelet transfusions or have antiplatelet antibodies.1,5,7,13 The 
use of HLA-matched platelets has historically been used and 
recommended as prophylaxis for major surgical procedures, 
including cesarean section. rFVIIa can be used to avoid 
platelet transfusion altogether, which would mitigate the risk 
of platelet alloimmunization, in cases of non-life threatening 
hemorrhage when local measures and anti-fibrinolytics have 
failed.3 This is of special concern in women of child-bearing 
age who may transfer platelet alloantibodies into the fetal circu-
lation, causing fetal thrombocytopenia, which has been associ-
ated with intrauterine death and intracranial hemorrhage.7
The optimal dosage for use in GT patients has not been 
established, and currently there is no means of determining 
the optimal dose or dosing regimen. However, the recom-
mended dose is bolus injections of 90 mcg/kg intravenously 
every 2 hours for three doses or until bleeding stops, followed 
by one or more maintenance doses.3,6,7 Repeat doses are 
necessary due to the short half-life of rFVIIa.
No randomized controlled trials examining the use of 
rFVIIa in patients with GT currently exist. However, the 
safety and efficacy of rFVIIa in GT patients has been well 
documented. To date, the single largest published investi-
gation into the efficacy of rFVIIa in patients with GT was 
reported by Poon et al through an international survey. The 
survey consisted of 59 GT patients who were given rFVIIa as 
either treatment of hemorrhage or for surgical prophylaxis. 
The overall success rate was 64% in bleeding episodes, and 
94% during surgical procedures. The success rate was higher 
in those patients who received boluses of 80 mcg/kg or higher 
of rFVIIa, given intravenously, no more than 2.5 hours apart. 
Two of the 59 patients were given a high dose of rFVIIa as a 
continuous infusion, in combination with an anti-fibrinolytic 
agent, during surgical procedures and experienced throm-
boembolic events: pulmonary embolism with deep venous 
thrombosis, and ureteric clot, respectively.7 In patients given 
boluses of rFVIIa, there were no adverse or thromboembolic 
events reported.1,2 An open-label study with 28 GT patients 
found that 93% of patients with bleeding episodes responded 
to rFVIIa.4 In addition, a total of 40 published case reports 
in the literature showed 69% of patients during bleeding epi-
sodes and 96% of patient undergoing surgery responded to 
rFVIIa treatment. The incidence of thrombotic events in GT 
patients treated with rFVIIa is unknown; controlled clinical 
trials are needed to further assess the risk.
rFVIIa should be administered as early in bleeding 
episodes as possible, as a UK study has shown that rFVIIa 
was successful in 71% of patients treated within 12 hours 
of onset, but only 18% of patients responded to rFVIIa after 
12 hours had passed.1–3 Minor surgeries in GT patients have 
been successfully performed without the need for platelet 
transfusion when rFVIIa is administered for prophylaxis, and 
its use is recommended by the United Kingdom Haemophilia 
Centre Doctors’ Organisation for minor surgical prophylaxis 
including dental extractions.5
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Rituximab
Rituximab (anti-CD20) is a human-mouse chimeric mono-
clonal antibody that targets the B cell CD20 antigen, and has 
been used in the treatment of acquired immune cytopenias as 
well as in antibody-mediated hemostatic disorders.
The use of systemic corticosteroids, chemotherapy, 
plasma exchange, protein A Sepharose immunoadsorption, 
IVIG, rFVIIa, and rituximab have all been reported as suc-
cessful therapy for patients with acquired GT.4,5,8 Multiple 
case reports have demonstrated the efficacy of rituximab 
in patients with acquired GT and bleeding manifestations 
or ecchymoses who were otherwise refractory to therapy 
with systemic steroids, cyclophosphamide, azathioprine, 
plasmapheresis, and IVIG. Administration of rituximab at 
375 mg/m2/week for 4 weeks resulted in normal platelet 
aggregation and cessation of symptoms in these patients.8
Bevacizumab
Bevacizumab (Avastin) is an anti-VEGF antibody that has been 
used in various cancers in conjunction with chemotherapy.2 
The use of bevacizumab as a potential treatment option for 
management of severe gastrointestinal bleeding in patients 
with refractory GT needs to be explored further. A single case 
report in the literature documented success using bevacizumab 
in a patient with type I GT, who was experiencing severe, 
recurrent GI bleeding due to angiodysplasia. The patient was 
refractory to platelet transfusions, tranexamic acid, and embo-
lization, but responded to bevacizumab. A 5 mg/kg infusion of 
bevacizumab was first given every 2 weeks as rescue therapy, 
followed by use every 4 weeks as maintenance therapy, and 
resulted in cessation of bleeding.2
Hematopoietic stem cell  
transplantation
Hematopoietic stem cell transplantation (HSCT) offers a cure 
for patients with severe, recurrent bleeding episodes, and/or 
platelet alloantibodies who are refractory to platelet transfu-
sions.4–6 There currently is no clearly defined algorithm for 
transplantation in GT, and HSCT for GT is rare. The first 
successful bone marrow transplant in GT occurred in 1985 in 
a 4-year-old boy with anti-GPIIb/IIIa antibodies.6 To date, at 
least 19 reported patients with severe GT have received suc-
cessful stem cell transplantations from umbilical cord blood, 
HLA-identical siblings, matched unrelated donors, or matched 
family donors.3,4 Most patients received stem cells from a 
sibling with busulfan and cyclophosphamide conditioning. 
Patients have undergone both conventional and reduced-
intensity conditioning with sustained engraftment.4,5
Future therapy
Our understanding of the pathogenesis of GT and the function 
of αIIbβ3 has improved substantially since Glanzmann first 
described the disease; however, the treatment of GT remains 
unsatisfactory. The quality of life of patients with GT remains 
impaired by multiple, spontaneous mucocutaneous bleeding 
episodes, and the high risk of hemorrhaging with surgery or 
any trauma. The available therapies, aside from the costly and 
risky allogeneic stem cell transplantation, are focused on treat-
ing bleeding episodes, and none of them provide a cure.
Gene therapy has gained significant attention in the 
last decade, and the concept for it was provided in animal 
models.11 The use of αIIb promoter-driven murine leukemia 
retrovirus vectors for gene transfer of CD34+ cells to target 
transgene expression in developing megakaryocytes was per-
formed by Wilcox et al.11 Successful transduction of CD34+ 
cells was demonstrated in vitro from two patients with GT 
using murine leukemia retrovirus vectors with expression 
of αIIbβ3 on transduced megakaryocytes. This resulted in 
correction of GT. In an αIIb deficient canine model for GT, 
Fang et al showed improvement in hemostasis and modest res-
toration of platelet surface αIIbβ3 by lentivirus transduction 
of mobilized CD34+ stem cells.14 In a recent study, Sullivan 
et al developed a strategy to achieve a high level of protein 
expression in human megakaryocytes. Hemizygous inser-
tion of Gp1ba promotor-driven human αIIb complementary 
DNA into the AAVS1 locus of induced pluripotent stem cells 
led to a high αIIb messenger RNA and protein expression, 
and resulted in the correction of αIIbβ3 in megakaryocytes.5 
These studies offer promise for patients with GT as curative 
treatment, and will help restore the quality of life that most 
patients lack with this disease.
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